Chemiluminescence-driven Dye Excitation for Dark Photodynamic Therapy
DOI:
https://doi.org/10.15584/ejcem.2017.2.1Keywords:
singlet oxygen, chemiluminescence, bioluminescence, photodynamic therapyAbstract
Photodynamic therapy is a treatment that uses a combination of light-absorbing photosensitizers and dissolved oxygen to kill cancer. One specific limitation of photodynamic therapy is that the visible light used for photosensitizer excitation has a short tissue penetration depth of several millimeters. This limits the application of photodynamic therapy to surface cancers in the absence of a technique to illuminate deeper tissue. Efforts to extend tissue depth to which photodynamic therapy can be applied have been attempted with use of up-conversion and persistent-luminescent nanoparticles that absorb near infrared light and emit visible light for photosensitizer excitation, yet an initial excitation with an external light source is still required. More recently, systems employing chemiluminescence as an excitation energy source designed to bypass the use of external light have been developed and investigated as potential agents that could overcome the problem of achieving photodynamic therapy in deep tissue. We wish to provide an overview of several systems that have been recently reported that employ both radiative and non-radiative chemiluminescent energy transfer for photosensitizer excitation that have been developed in the hope of achieving “dark” photodynamic therapy. This article reviews several of these important new developments in the design of photodynamic therapeutic systems that utilize chemiluminescence.Downloads
References
Rai P, Mallidi S, Zheng X, et al. Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev. 2010;62:1094-1124.
Magalhães CM, da Silva JCGE, daSilva LP. Chemiluminescence and bioluminescence as an excitation source in the photodynamic therapy of cancer: A critical review. ChemPhysChem. 2016;17(15):2286-94.
Laptev R, Nisnevitch M, Siboni G, Malik Z, Firer MA. Intracellular chemiluminescence activates targeted photodynamic destruction of leukemic cells. Br J Cancer. 2006;95(2):189-96.
Yuan H, Chong H, Wang B, et al. Chemical molecule-induced light-activated system for anticancer and antifungal activities. J Am Chem Soc. 2012;134(32):13184-87.
Hsu CY, Chen CW, Yu HP, Lin YF, Lai PS. Bioluminescence resonance energy transfer using luciferase-immobilized quantum dots for self-illuminated photodynamic therapy. Biomaterials. 2013;34(4):1204-12.
Kim YR, Kim S, Choi JW, et al. Bioluminescence-activated deep-tissue photodynamic therapy of cancer. Theranostics 2015;5(8):805-17.
Zhang Y, Pang L, Ma C, et al. Small molecule-initiated light-activated semiconducting polymer dots: an integrated nanoplatform for targeted photodynamic therapy and imaging of cancer cells. Anal Chem. 2014;86(6):3092-99.
Singh SV, Berwin JK, Hoyeon P, Gilson K, Dongwon L. Novel chemi-dynamic nanoparticles as a light-free photodynamic therapeutic system for cancer treatment. Macromol Res. 2017. https://doi.org/10.1007/s13233-017-5078-91–7.
Degirmenci A, Algi F. Synthesis, chemiluminescence and energy transfer efficiency of 2,3-dihydrophthalazine-1,4-dione and BODIPY dyad. Dyes and Pigments. 2017;140:92-99.
Nisa Y, Uyar TB, Seven O, Akkaya EU. Singlet oxygen generation with chemical excitation of an erythrosine–luminol conjugate. ACS Omega. 2017;2(4):1367-1371.
Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by Human tumor cells. Cancer Res. 1991;51(3):794-98.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 European Journal of Clinical and Experimental Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




